GSK3B and cholangiocarcinoma: 21 found Escin suppressed the metastasis of triple‐negative breast cancer cells through inhibiting epithelial–mesenchymal transition. Furthermore, study also showed Escin can reverse multidrug resistance through inhibition of the GSK3β/β–catenin pathway in cholangiocarcinoma cells 22. Clinically, Escin has been proved to be well tolerated and efficiency on improving the gastrointestinal motility in patients with colorectal cancer as well 19.